RXRX CEO trades: 60,000 conversion, 40,000 sold at $5.21
Recursion Pharmaceuticals (RXRX) CEO and Director reported insider transactions on 11/04/2025 under a Rule 10b5-1 plan adopted May 12, 2025.
Rhea-AI Filing Summary
Recursion Pharmaceuticals (RXRX) CEO and Director reported insider transactions on 11/04/2025 under a Rule 10b5-1 plan adopted May 12, 2025. The filing shows a conversion of 60,000 shares of Class B into Class A at $0 (Code C), a sale of 40,000 Class A shares at $5.21 (Code S), and a gift of 20,000 Class A shares (Code G). Following these transactions, the reporting person directly beneficially owned 954,229 Class A shares. The filing also lists ongoing stock option grants with multi-year vesting schedules.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
13 txns
Insider
Gibson Christopher
Role
Chief Executive Officer
Sold
40,000 shs ($208K)
Approx. gross sale proceeds
$208K
Approx. exercise cost
$0.00
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Class B Common Stock | 60,000 | $0.00 | $0.00 |
| Conversion | Class A Common Stock | 60,000 | $0.00 | $0.00 |
| Sale | Class A Common Stock | 40,000 | $5.21 | $208K |
| Gift | Class A Common Stock | 20,000 | $0.00 | $0.00 |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Class B Common Stock — 4,863,334 contracts (Direct);
Class A Common Stock — 954,229 shares (Direct);
Class B Common Stock — 0 contracts (Indirect, by LAHWRAN-3 LLC);
Class B Common Stock — 0 contracts (Indirect, by LAHWRAN-4 LLC);
Class B Common Stock — 0 contracts (Indirect, by Gibson Family Trust);
Stock Option (Right to Buy) — 0 contracts (Direct)
Footnotes (10)
- F1. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
- F2. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025.
- F3. The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
- F4. The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
- F5. The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.
- F6. The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- F7. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- F8. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- F9. The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- F10. The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
FAQ
What insider transactions did RXRX's CEO report?
A conversion of 60,000 Class B to Class A (Code C), a sale of 40,000 Class A at $5.21 (Code S), and a gift of 20,000 Class A (Code G) on 11/04/2025.
Was the RXRX trade under a 10b5-1 plan?
Yes. The transactions were pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2025.
What do the Form 4 transaction codes mean here?
C = conversion of Class B to Class A; S = open market sale; G = gift.
Are there derivative or option holdings mentioned?
Yes. The filing lists multiple stock options with stated exercise prices and vesting schedules extending to 2035.
AI-generated analysis. How Rhea-AI works. Not financial advice.
